MediPrint™ Ophthalmics is an emerging pharmaceutical company based in San Diego developing and commercializing a proprietary ocular drug delivery portfolio.

MediPrint™ Ophthalmics

Vision Biotechnology specializes in developing and manufacturing diagnostic test kits for healthcare professionals to accurately diagnose various diseases. The company incorporates the latest advancements in biotechnology into its products, self-described as elevating healthcare through innovative testing solutions.

Vision Biotechnology

MediPrint Ophthalmics | 539 followers on LinkedIn. Enhancing Vision for Life | Enhancing vision for life with a patented contact lens based drug delivery portfolio.

Corporate Development | Partnerships | Strategic Growth

Sanjeev Ganatra

Director of Quality at MediPrint Ophthalmics

P.N. Balasubramanian

Bruce Holm

Senior Research Fellow

Furqan Maulvi

MediPrint Ophthalmics

Thank you The Medicine Maker for the terrific article about MediPrint Ophthalmics and our founder Praful Doshi . #drugdelivery #contactlenses #glaucoma #enhancingvisionforlife https://lnkd.in/g-n76mSx

Mediprint will be at the American Academy Of Optometry meeting in #Indianapolis November 7-9. We look forward to seeing the optometric community, our partners and clinical colleagues. Certainly reach out to us if you will be attending so we can schedule time to meet. For those attending please make sure to attend the following presentations: Wednesday, November 6th (1:00pm EST) Dr. Walter Whitley and Dr. Justin Schweitzer, OD, FAAO - "Advances in Ocular Drug Delivery" (Indianapolis Convention Center; Room Sagamore 3-5; GO-04) Friday, November 8th (11:30am EST) Dr. I. Ben Gaddie, O.D., F.A.A.O. - "Clinical Successes with Sustained Delivery of Bimatoprost and Hyaluronic Acid from Contact Lenses Using Digital Printing Technology to Manage Glaucoma" (Indianapolis Convention Center; Wabash Ballroom) Part of Drugs, Devices, and New Discoveries: Dive into Optometry’s Evolution and Expansion Praful Doshi David Fancher CBCC Global Research Sanjeev Ganatra #optometry , #drugdelivery , #ophthalmology , #glaucoma , #contactlens MediPrint Ophthalmics #Academy24

We are grateful for being a sponsor at Octane 2024 and are excited for our enhancement of comfort for contact lens wearer in our phase 3 clinical study for sustained delivery for Glaucoma. Check out the video below of our founder and CEO Praful Doshi talking about our product pipeline! #enhancingvisionforlife #glaucoma #contactlenses #helpprotectsight #drugdelivery #ophthalmology #dryeye

We are excited to announce we have successfully completed our Phase 2b Glaucoma Clinical study with positive results. SIGHT-2 study evaluated safety and efficacy of LL-BMT-1 in 28 patients diagnosed with open-angle Glaucoma for three weeks. Results show clinically meaningful and sustained IOP reduction over the duration of 3 weeks which is statistically comparable to 0.01% bimatoprost eye drops. Learn more here: https://lnkd.in/gYVkCsh9 #enhancingvisionforlife #glaucoma #contactlenses #helpprotectsight #drugdelivery #ophthalmology #dryeye

MediPrint is excited to share that Thomas Bender, an industry veteran in the vision care industry, has joined our team as a Strategic Advisor! His extensive expertise will be pivotal in steering the future of our pioneering drug-eluting contact lens technology. Learn more here: https://lnkd.in/g_D-Z9QF #enhancingvisionforlife #glaucoma #contactlenses #helpprotectsight #drugdelivery #ophthalmology #dryeye

Metric
Company Name	MediPrint™ Ophthalmics	Vision Biotechnology
Symbol
MSH ID	COM:MEDIPRINTLENS	COM:VISIONBIOTECHNOLOGY
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Pharmaceuticals	Biotechnology
Country	US	US
Stage	Series A
Employee Count
Website	mediprintlens.com	visionbiotechnology.com
LinkedIn	mediprint	visionbiotechnolgy
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		434
Web Traffic Growth		1.39
Valuation
Raised Capital	2.50M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

MEDI

COM:MEDIPRINTLENS

MediPrint™ Ophthalmics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue